Linscomb Wealth Inc. boosted its place in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 1.0% through the second quarter, in line with the corporate in its most up-to-date Kind 13F submitting with the SEC. The institutional investor owned 69,675 shares of the corporate’s inventory after buying a further 720 shares through the quarter. Linscomb Wealth Inc.’s holdings in Johnson & Johnson had been price $10,184,000 on the finish of the newest reporting interval.
A number of different giant buyers additionally lately purchased and bought shares of the corporate. Meridian Monetary Companions LLC acquired a brand new stake in Johnson & Johnson through the 2nd quarter valued at $1,626,000. Summit Monetary Wealth Advisors LLC lifted its place in shares of Johnson & Johnson by 26.3% within the first quarter. Summit Monetary Wealth Advisors LLC now owns 5,392 shares of the corporate’s inventory valued at $853,000 after buying a further 1,122 shares within the final quarter. Gilbert & Cook dinner Inc. boosted its stake in shares of Johnson & Johnson by 3.3% through the fourth quarter. Gilbert & Cook dinner Inc. now owns 9,111 shares of the corporate’s inventory valued at $1,428,000 after buying a further 288 shares over the last quarter. Franklin Parlapiano Turner & Welch LLC elevated its place in Johnson & Johnson by 0.7% through the 1st quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the corporate’s inventory price $7,464,000 after buying a further 325 shares within the final quarter. Lastly, Capital Asset Advisory Companies LLC lifted its holdings in Johnson & Johnson by 8.8% within the 1st quarter. Capital Asset Advisory Companies LLC now owns 26,539 shares of the corporate’s inventory valued at $4,044,000 after buying a further 2,151 shares within the final quarter. Institutional buyers and hedge funds personal 69.55% of the corporate’s inventory.
Johnson & Johnson Worth Efficiency
JNJ opened at $164.64 on Friday. The corporate has a 50 day shifting common of $159.17 and a two-hundred day shifting common of $154.00. Johnson & Johnson has a 52-week low of $143.13 and a 52-week excessive of $168.85. The corporate has a fast ratio of 0.85, a present ratio of 1.07 and a debt-to-equity ratio of 0.44. The corporate has a market cap of $396.24 billion, a P/E ratio of 10.26, a P/E/G ratio of two.71 and a beta of 0.53.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final introduced its quarterly earnings outcomes on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.71 by $0.11. The agency had income of $22.45 billion through the quarter, in comparison with the consensus estimate of $22.33 billion. Johnson & Johnson had a return on fairness of 36.60% and a web margin of 46.34%. The agency’s quarterly income was up 4.3% in comparison with the identical quarter final yr. Throughout the identical interval within the prior yr, the agency earned $2.80 EPS. On common, analysts anticipate that Johnson & Johnson will submit 10.02 earnings per share for the present yr.
Johnson & Johnson Dividend Announcement
The enterprise additionally lately declared a quarterly dividend, which was paid on Tuesday, September tenth. Traders of document on Tuesday, August twenty seventh got a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of three.01%. The ex-dividend date of this dividend was Tuesday, August twenty seventh. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.
Wall Road Analyst Weigh In
Plenty of brokerages have lately commented on JNJ. TD Cowen lowered their worth goal on shares of Johnson & Johnson from $195.00 to $185.00 and set a “purchase” score for the corporate in a report on Thursday, July 18th. Cantor Fitzgerald reiterated an “obese” score and issued a $215.00 worth goal on shares of Johnson & Johnson in a report on Monday. TD Securities decreased their worth goal on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. StockNews.com lowered Johnson & Johnson from a “strong-buy” score to a “purchase” score in a analysis notice on Friday, September sixth. Lastly, Royal Financial institution of Canada reissued an “outperform” score and issued a $175.00 worth goal on shares of Johnson & Johnson in a analysis notice on Tuesday, July thirtieth. Seven analysts have rated the inventory with a maintain score and 7 have given a purchase score to the inventory. In accordance with information from MarketBeat, the corporate presently has a median score of “Average Purchase” and a consensus worth goal of $173.21.
View Our Newest Inventory Report on Johnson & Johnson
Insider Shopping for and Promoting at Johnson & Johnson
In different information, VP Robert J. Decker bought 5,635 shares of the corporate’s inventory in a transaction on Friday, August thirtieth. The shares had been bought at a median worth of $165.06, for a complete worth of $930,113.10. Following the completion of the transaction, the vp now straight owns 18,973 shares within the firm, valued at $3,131,683.38. The sale was disclosed in a authorized submitting with the Securities & Alternate Fee, which is obtainable by means of the SEC web site. 0.16% of the inventory is owned by company insiders.
About Johnson & Johnson
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare subject worldwide. The corporate’s Revolutionary Medication section provides merchandise for varied therapeutic areas, akin to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper issues, neurodegenerative issues, and schizophrenia; oncology, akin to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Additional Studying
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e mail deal with beneath to obtain a concise every day abstract of the most recent information and analysts’ rankings for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE every day e mail e-newsletter.
